Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 1 |
2015 | 1 |
2016 | 1 |
2019 | 1 |
2020 | 2 |
2023 | 1 |
2024 | 1 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.
Hemasphere. 2023 Aug 30;7(9):e940. doi: 10.1097/HS9.0000000000000940. eCollection 2023 Sep.
Hemasphere. 2023.
PMID: 37663673
Free PMC article.
No abstract available.
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden AW, Deenik W, Gruber A, Coenen JL, Plesner T, Klein SK, Tanis BC, Szatkowski DL, Brouwer RE, Westerman M, Leys MR, Sinnige HA, Haukås E, van der Hem KG, Durian MF, Mattijssen EV, van de Donk NW, Stevens-Kroef MJ, Sonneveld P, Waage A.
Zweegman S, et al. Among authors: szatkowski dl.
Blood. 2016 Mar 3;127(9):1109-16. doi: 10.1182/blood-2015-11-679415. Epub 2016 Jan 22.
Blood. 2016.
PMID: 26802176
Free article.
Clinical Trial.
Item in Clipboard
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Nielsen LK, Stege C, Lissenberg-Witte B, van der Holt B, Mellqvist UH, Salomo M, Bos G, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden A, Deenik W, Coenen J, Hinge M, Klein S, Tanis B, Szatkowski D, Brouwer R, Westerman M, Leys R, Sinnige H, Haukås E, van der Hem K, Durian M, Gimsing P, van de Donk N, Sonneveld P, Waage A, Abildgaard N, Zweegman S.
Nielsen LK, et al. Among authors: szatkowski d.
Haematologica. 2020 Jun;105(6):1650-1659. doi: 10.3324/haematol.2019.222299. Epub 2019 Sep 12.
Haematologica. 2020.
PMID: 31515355
Free PMC article.
Clinical Trial.
Item in Clipboard
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.
Zweegman S, Stege CAM, Haukas E, Schjesvold FH, Levin MD, Waage A, Leys RBL, Klein SK, Szatkowski D, Axelsson P, Hieu Do T, Knut-Bojanowska D, van der Spek E, Svirskaite A, Klostergaard A, Salomo M, Blimark C, Ypma PF, Mellqvist UH, Poddighe PJ, Stevens-Kroef M, van de Donk NWCJ, Sonneveld P, Hansson M, van der Holt B, Abildgaard N.
Zweegman S, et al. Among authors: szatkowski d.
Haematologica. 2020 Dec 1;105(12):2879-2882. doi: 10.3324/haematol.2019.240374.
Haematologica. 2020.
PMID: 33256392
Free PMC article.
Clinical Trial.
No abstract available.
Item in Clipboard
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.
Partanen A, Waage A, Peceliunas V, Schjesvold F, Anttila P, Säily M, Uttervall K, Putkonen M, Carlson K, Haukas E, Sankelo M, Szatkowski D, Hansson M, Marttila A, Svensson R, Axelsson P, Lauri B, Mikkola M, Karlsson C, Abelsson J, Ahlstrand E, Sikiö A, Klimkowska M, Matuzeviciene R, Fenstad MH, Ilveskero S, Pelliniemi TT, Nahi H, Silvennoinen R.
Partanen A, et al. Among authors: szatkowski d.
Cancers (Basel). 2024 Feb 29;16(5):1024. doi: 10.3390/cancers16051024.
Cancers (Basel). 2024.
PMID: 38473382
Free PMC article.
Item in Clipboard
The overexpression of KIT proto-oncogene in acute leukemic cells is not necessarily caused by the gene mutation.
Szatkowski D, Hellmann A.
Szatkowski D, et al.
Acta Haematol. 2015;133(1):116-23. doi: 10.1159/000360214. Epub 2014 Sep 20.
Acta Haematol. 2015.
PMID: 25247397
Item in Clipboard
Cite
Cite